Suppr超能文献

膀胱癌的分子生物标志物:小型综述。

Molecular Biomarkers of Bladder Cancer: A Mini-Review.

机构信息

Institute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic.

出版信息

Physiol Res. 2023 Oct 27;72(S3):S247-S256. doi: 10.33549/physiolres.935187.

Abstract

Cancers are quite common, but mostly very serious diseases and therefore belong to the most important areas of scientific research activity. Bladder cancer is one of the most common malignancies, it is a heterogeneous disease with significant diagnostic, therapeutic, and prognostic problems. It represents a disease with a variable course and a different response to therapy. The "conventional" prognostic markers used so far cannot reliably predict the natural course of the disease or estimate the tumor response to the chosen type of treatment. Molecular markers can provide us with the opportunity to diagnose a bladder tumor early, identify patients who are at risk of recurrence, or predict how tumors will respond to therapeutic approaches. As a result, diagnostics are found to help clinicians find the best therapeutic options for patients with bladder cancer. In this study, we focused on a brief description of potential molecular markers in bladder tumors in the context of precise diagnostics. Last but not least, we also focused on a new approach to the treatment of cancer using nanomaterials.

摘要

癌症很常见,但大多是非常严重的疾病,因此属于科学研究活动最重要的领域之一。膀胱癌是最常见的恶性肿瘤之一,它是一种具有显著诊断、治疗和预后问题的异质性疾病。它代表了一种具有多变病程和对治疗反应不同的疾病。迄今为止使用的“常规”预后标志物不能可靠地预测疾病的自然病程或估计肿瘤对所选治疗类型的反应。分子标志物可以为我们提供早期诊断膀胱癌、识别有复发风险的患者或预测肿瘤对治疗方法的反应的机会。因此,诊断发现有助于临床医生为膀胱癌患者找到最佳治疗选择。在这项研究中,我们专注于简要描述膀胱癌中潜在的分子标志物在精准诊断方面的作用。最后但同样重要的是,我们还专注于使用纳米材料治疗癌症的新方法。

相似文献

1
Molecular Biomarkers of Bladder Cancer: A Mini-Review.
Physiol Res. 2023 Oct 27;72(S3):S247-S256. doi: 10.33549/physiolres.935187.
2
Molecular aspects of bladder cancer III. Prognostic markers of bladder cancer.
Eur Urol. 2002 Jan;41(1):15-29. doi: 10.1016/s0302-2838(01)00007-0.
3
Germline prognostic markers for urinary bladder cancer: obstacles and opportunities.
Urol Oncol. 2012 Jul-Aug;30(4):524-32. doi: 10.1016/j.urolonc.2012.04.003.
4
Emerging Bladder Cancer Biomarkers and Targets of Therapy.
Urol Clin North Am. 2016 Feb;43(1):63-76. doi: 10.1016/j.ucl.2015.08.006.
5
Can we use methylation markers as diagnostic and prognostic indicators for bladder cancer?
Investig Clin Urol. 2016 Jun;57 Suppl 1(Suppl 1):S77-88. doi: 10.4111/icu.2016.57.S1.S77. Epub 2016 May 25.
6
Diagnosis and management of superficial bladder cancer.
Curr Probl Cancer. 2001 Jul-Aug;25(4):219-78. doi: 10.1067/mcn.2001.117539.
7
Biomarkers for precision medicine in bladder cancer.
Int J Clin Oncol. 2017 Apr;22(2):207-213. doi: 10.1007/s10147-016-1068-8. Epub 2016 Nov 29.
8
Recent Advances in the Diagnosis and Management of Bladder Cancer.
Cell Biochem Biophys. 2015 Sep;73(1):11-5. doi: 10.1007/s12013-015-0632-6.
9
Molecular markers in bladder cancer.
Semin Radiat Oncol. 2005 Jan;15(1):3-9. doi: 10.1016/j.semradonc.2004.07.007.
10
Prognostic markers in bladder cancer: a contemporary review of the literature.
J Urol. 1998 Sep;160(3 Pt 1):645-59. doi: 10.1016/S0022-5347(01)62747-2.

本文引用的文献

1
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges.
Cancer Treat Rev. 2023 Apr;115:102530. doi: 10.1016/j.ctrv.2023.102530. Epub 2023 Feb 28.
2
Biomarkers of Bladder Cancer: Cell-Free DNA, Epigenetic Modifications and Non-Coding RNAs.
Int J Mol Sci. 2022 Oct 30;23(21):13206. doi: 10.3390/ijms232113206.
3
Bladder cancer diagnosis with a four-miRNA panel in serum.
Future Oncol. 2022 Sep;18(29):3311-3322. doi: 10.2217/fon-2022-0448. Epub 2022 Sep 1.
4
Sp1 is overexpressed and associated with progression and poor prognosis in bladder urothelial carcinoma patients.
Int Urol Nephrol. 2022 Jul;54(7):1505-1512. doi: 10.1007/s11255-022-03212-6. Epub 2022 Apr 25.
5
In Situ Constructed Nano-Drug Depots through Intracellular Hydrolytic Condensation for Chemotherapy of Bladder Cancer.
Angew Chem Int Ed Engl. 2022 Apr 25;61(18):e202116893. doi: 10.1002/anie.202116893. Epub 2022 Mar 9.
6
Tumoral markers in bladder cancer (Review).
Exp Ther Med. 2021 Jul;22(1):773. doi: 10.3892/etm.2021.10205. Epub 2021 May 18.
7
Emerging Biomarkers for Predicting Bladder Cancer Lymph Node Metastasis.
Front Oncol. 2021 Mar 19;11:648968. doi: 10.3389/fonc.2021.648968. eCollection 2021.
8
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
9
Low Expression of Keratin17 is Related to Poor Prognosis in Bladder Cancer.
Onco Targets Ther. 2021 Jan 19;14:577-587. doi: 10.2147/OTT.S287891. eCollection 2021.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验